“The overall conclusion of the study is that Cymerus MSCs are highly consistent and that the Cymerus manufacturing process successfully bypasses much of the inherent variability that affects tissue-derived MSCs.
Product consistency is a mandatory requirement of healthcare regulatory agencies such as the FDA and so the conclusions from this study further support the utility of the Cymerus platform.
The study validates the potential of Cymerus MSCs as an off-the-shelf cell therapy and provides a better understanding of the sources of MSC variability, with a view to making clinical outcomes more predictable.”
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)